每日经济新闻 （责任编辑：张晓波 ） 【免责声明】本文仅代表作者本人观点，与和讯网无关。和讯网站对文中陈述、观点判断保持中立，不对所包含内容 的准确性、可靠性或完整性提供任何明示或暗示的保证。请读者仅作参考，并请自行承担全部责任。邮箱： news_center@staff.hexun.com 光大证券指出，未来医药板块投资应着重于临床价值本质逻辑。医药生物板块受创新驱动（出海、 AI、新技术）、业绩验证、政策红利及春季躁动的共振效应，短期创新药及CXO是主线，AI医疗/AI制 药、脑机接口、小核酸药物是高弹性细分主题方向。从临床价值三段论出发，看好创新药产业链与创新 医疗器械。在创新医疗器械领域，看好创新升级的高端医疗器械和高值耗材。随着全球重回降息通道及 国内政策结构性转向，医保谈判"腾笼换鸟"支持创新药，集采"反内卷"稳定产业盈利，医药板块估值自 2025年一季度起稳步修复，产业提质升级趋势明确，国际竞争力增强。 创业板医药ETF国泰（159377）跟踪的是创医药指数（399275），单日涨跌幅限制达20%，该指数 聚焦于创新生物医药领域，从市场中选取涉及生物技术、制药及相关医疗服务等业务的上市公司证券作 ...

Group 1 - The A-share market experienced fluctuations on January 20, with the medical device ETF (562600) showing a maximum decline of 0.76, while individual stocks like Hualan Biological (301093) and Bluestar Medical (002382) saw gains of 3.71% and 1.01% respectively [1] - The medical device ETF (562600) has attracted significant capital inflow, with a net inflow of 10.4 million yuan over the past five days and 24.3 million yuan over the past ten days [1] - Bluestar Medical announced that its subsidiary Biosensors received EU CE certification for the Lithonic coronary intravascular shockwave treatment system, enhancing the company's competitiveness in the cardiovascular field [1] Group 2 - The medical device industry is experiencing robust growth, and the medical device ETF (562600) provides a convenient way to capture growth opportunities, with a 23.8% allocation to brain-computer interface stocks, the highest among listed ETFs [2] - The medical device ETF (562600) has a high concentration in the medical device sector, accounting for 89.2%, effectively capturing growth opportunities in niche segments [2] - Investors can also consider alternative options such as the Huaxia CSI All-Index Medical Device ETF Initiated Link A (021250) and Huaxia CSI All-Index Medical Device ETF Initiated Link C (021251) for convenient investment [2]